ABSTRACT
Background:Malnutrition is common in patients with cancer, whichadversely affectsthesurvival and quality of life ofcancer patients.However, there is no national data on the prevalence of malnutrition inChinese cancer patients. Thisstudy aims to evaluate the prevalenceof malnutrition and quality of life(QOL)ofChinese patients with localregional, recurrentor metastatic cancer,to address the prognostic value of nutritional status and QOLon the survival of cancer patients in China and to validate the patient-generated subjective global assessment (PG-SGA) questionnaire in Chinese cancer patients.Methods:Thisisanobservational,multi-centered,and hospital-based prospective cohort study.We aimed to recruit 50,000 cancer patients (age 18and above)overan 8-year period.Data collection will occur within 48hrafter patientsare admitted to hospital, 30-days after hospital admission, and the follow-up will be conducted1-8years after enrolment. The primary outcomeisoverall survival, and secondaryoutcomes arelength of hospital stay and hospital costs. Factors measured are demographic characteristics, tumor characteristics, anthropometry measurements,hematological measurement, body composition, PG-SGAscores,Karnofsky performance status scores,and QLQ C30 scores. This protocol wasapproved by local ethical committees of all the participant hospitals.Conclusions: This multi-centered, large-scale, long-time follow-up prospective study will help diagnose malnutrition in cancer patients in China, and identify the related risk factors associated with the negative outcomes. The anticipated results will highlight the need for a truly scientific appraisal of nutrition therapy, and help to improve outcomes among cancer patients in China.Trial Registration: The trial has been registered with the Chinese Clinical Trial Registry, ChiCTR1800020329. Registered on 19 December 2018
ABSTRACT
Focal adhesion kinase( FAK) ,a cytoplasmic non-receptor protein tyrosine kinase,serves as both a molecular scaffold and a mediator participating in multiple signal transduction pathways.FAK is involved in tumor cell survival,proliferation,migration and metastasis.Recent studies have shown that FAK is expressed in many tumor cells.Currently,FAK has been regarded as a potential target for cancer therapy.This review is to summarize the relationship between FAK and tumor progression.
ABSTRACT
Hedgehog-Gli signaling pathway involves in vertebrate embryonic development ,tissue differ-entiation,organogenesis,and plays an important role in homeostasis ,the maintenance of stem cell function ,regula-tion of epithelial mesenchymal transition .Hedgehog-Gli signaling pathway activation correlates with a variety of tumor development ,invasion,apoptosis and drug resistance .This review seeks to clarify the composition of Hedge-hog-Gli signaling pathway ,mechanism of action ,the role of Hedgehog-Gli signaling pathway in lung cancer de-velopment and function of lung cell of the EGFR -TKI resistance .
ABSTRACT
EphA7 is one of the most important members of the Eph family .It is a key regulatory factor of cell adhesion and repulsion ,it also contributes to establish men ,maintain ance and tissue remodeling in cell mor-phology .In recent years ,its function in tumors has been revealed gradually .It plays a variety of roles in different tumors.The overexpression of EphA7 can be detected in acute leukemia ,glioblastomamultiforme,lung cancer and hepatic carcinoma ,which suggests EphA 7 may be involved in the development of these tumors .While in colon cancer,prostate cancer,follicular lymphoma and gastric cancer ,a significant reduction of EphA7 expression with promoter hypermethylation is discovered ,which suggests EphA 7 play a tumor suppressor role in these tumors .E-ven though the function of EphA 7 is still under exploration , EphA7 and tumor development are inextricably linked,it may have roles in the pathogenesis and development of these carcinomas .
ABSTRACT
Currently,XB130 as a newly discovered characterized adaptor protein ,it has been implicated as a substrate and regulator of many intracellular signal transduction ,such as FAK/SRC,PI3K/Akt and MEK-ERK signaling and so on.It has been found that XB130 is high expression in many cell lines ,for instance thyroid carcinoma,osteosarcoma,gastric cancer,esophageal cancer and breast cancer etc .The mechanism of XB130 in tumor is becoming increasingly attention .XB130 is recently attributed to be a new oncogene ,and plays important roles in cell pro -liferation,cell survival and tumorigenesis .A deeper understanding of these mechanisms may lead to the discovery of XB130 as an important mediator in tumor development and as a novel therapeutic target for cancer.
ABSTRACT
Sox2 is one of the important members of the Soxfamily ,It plays an import role in the regulation of early embryo and normal tissue development ,maintain the versatility of stem cells and progenitor cells self -re-newal ability and decide cell fate ,etc.Sox2 genetic mutation or missing may lead to dysplasia or congenital disea-ses.Previous studies showed that Sox 2 expressed in a variety of malignant tumors ,and associated with the inci-dence of malignant tumor ,lymph node metastasis and pathological grading and clinical staging .There fone Sox2 is considered as a potential carcinogenic factor ,its over expression may form one of development of mechanisms for the occurrence and different kinds of malignant tumor .
ABSTRACT
Tumor growth and migration are correlated with continuous neovascularization .Slit2-Robo1 signal pathway initially positioned in the nervous system plays an important role in the growth and neuronal axon guidance during migration.However,vascular system resembles the structural features and growth mechanism of neural system .Recent researches have shown that Slit 2-Robo1 signaling pathway plays an important role in vas-cular system,especially in tumor vessel .And Slit2-Robo1 has been shown to play a role in brain metastasis in breast cancer and supporting tumor growth in melanoma .Therefore,the role of Slit2-Robo1 in tumor growth and migration depends on the cancer type .Currently ,researches in this field show controversial results .And the status of Slit2-Robo1 signaling pathway in lung cancer is reviewed in this essay .
ABSTRACT
P300/CBP is one of the most important high molecular weight protein histone acetyltransferase ( HAT) Although it is encoded by multiple different genes , P300/CBP is highly homologous , Because they have the similar amino acid sequence and functions ,and belong to the same class of proteins ,normolly they are all called P300/CBP.P300/CBP is involved in the activation of many kinds of transcription factors ,the protein itself alsohas acetyltransferase activity ,and is capable of acetylation of 4 core histones and transcription factor .More and more studies have confirmed the relationship of P 300/CBP variation withmultiple human diseases , including in-flammation,diabetes,heart disease and especially cancer .In tumor P300/CBP is associated with some pathways , and these pathways play a different roles in the tumor .Although P300/CBP is usually regarded as a tumor sup-pressor factor ,is plays different roles in different tumors ,This review mainly introduces the relationship of P 300/CBP with some solid tumor disease genes ,related transcription factors and their signaling pathways .
ABSTRACT
Lysine specific demethylase 1( LSD1) is a kind of flavin adenine dinucleotid ( FAD) dependent amine oxidase and can specifically demethylate H 3K4me2/me1 and H3K9me2/mel, thus it can regulate gene transcriptional activity .LSD1 is essential for mammalian development and is involved in many biological proces-ses,including cell differentiation,gene activation,and gene repression.Nowadays,it is demonstrated that LSD1 might promote cell phase transition(deficiency in LSD1 leads to partial cell cycle arrest in G2/M)and cell prolif-eration,suggesting that the over -expression of LSD1 might promote tumorigenesis.LSD1,as a demethylase,may be a new target for anti -cancer therapy.Hereby,we review on the structure,action mode of LSD1 and its rela-tionship with oncogenesis .
ABSTRACT
<p><b>BACKGROUND AND OBJECTIVE</b>Human telomerase reverse transcriptase is the catalytic subunit of telomerase, and its activity is correlated with cell's sensitivity to chemotherapy. The aim of this study is to investigate the differential expression of human telomerase reverse transcriptase (hTERT) mRNA in human lung adenocarcinoma cell line Anip973 and Anip973/NVB, and to observe the correlation between hTERT mRNA and drug-resistance.</p><p><b>METHODS</b>The real-time fluorescence quantitative RT-PCR was used to detect the change of hTERT mRNA in human lung adenocarcinoma drug-resistant cell Anip973/NVB and parental cell Anip973 treated by NVB.</p><p><b>RESULTS</b>In the control group, the expression of hTERT mRNA showed no significant difference between drug-resistant cell Anip973/NVB and parental cell Anip973. After been treated by NVB, the expression of hTERT mRNA in parental cell was significantly decreased (P < 0.01), and drug-resistant cell Anip973/ NVB had no evidently variant (P > 0.05). The down-regulated hTERT mRNA in Anip973 cell was higher than that in Anip973/ NVB cell.</p><p><b>CONCLUSION</b>Telomerase correlates with the drug-resistant cell A973/NVB, and telomerase may be a new target for multi-drug resistant inversion.</p>
Subject(s)
Humans , Antineoplastic Agents , Pharmacology , Cell Line, Tumor , Drug Resistance, Neoplasm , Genetics , Physiology , Lung Neoplasms , Genetics , RNA, Messenger , Genetics , Reverse Transcriptase Polymerase Chain Reaction , Telomerase , Genetics , Vinblastine , PharmacologyABSTRACT
Presently platinum-based doublets chemotherapy is the first-line treatment for advanced non-small-cell lung cancer patient .However, the efficacy of standard first-line treatment has stagnated.Maintenance therapy for patients with advanced NSCLC who responded to initial therapy has become a focus.Summarization:first, Pem maintenance therapy is well tolerated and offers superior OS and PFS, making it a new treatment paradigm for patients with advanced NSCLC who responded to initial therapy, especially Pem has greater efficacy in patients with non-squamous. Secondly, first-line chemotherapy followed Erlotinib prolongs survival in patient with advanced NSCLC. It has proved that Erlotinib as maintenance therapy is an active and well tolerated treatment after standard therapy in nearly all the patients with advanced NSCLC.No matter what pathological type, race, sex, age and cigarette smoking or not, Gefitinib maintenance therapy offers superior OS and PFS for patients with adenocarcinoma, who has accepted platinum-based doublets chemotherapy.
ABSTRACT
<p><b>BACKGROUND</b>The occurrence of cancer needs many kinds of oncogenes and their cooperation, such as Bcl-2, p27, and vascular endothelial growth factor (VEGF) etc. They have different contributions in lung cancer's occurrence and development by different paths. In this study the expression of P27, Bcl-2, VEGF and their relationship in lung cancer were investigated.</p><p><b>METHODS</b>The expression of P27, Bcl-2 and VEGF was detected in 85 lung cancer and 21 benign pulmonary tissues by the immunohistochemistry staining.</p><p><b>RESULTS</b>Positive rate of VEGF and Bcl-2 protein expression was 65.88% (56/85) and 61.18% (52/85) respectively in lung cancer tissue, which was higher than that in benign pulmonary tissues (14.29% and (19.05%)) (P < 0.05). Positive rate of P27 protein expression in lung cancer tissue (37.65%, 32/85) was significantly lower than that in benign pulmonary tissues (80.95%, 17/21) (P < 0.05). VEGF expression was closely related to the grade of cell differentiation, P-TNM stage and lymph node status; Bcl-2 expression was closely related to histology of lung cancer, P-TNM stage and grade of cell differentiation; and P27 expression was closely related to grade of cell differentiation. There was correlation between P27 and Bcl-2 and between P27 and VEGF protein, but no correlation between Bcl-2 and VEGF.</p><p><b>CONCLUSIONS</b>Detection of P27, Bcl-2 and VEGF will be valuable for dignosing lung cancer and evaluating malignancy extent.</p>